On December 3, 2020, the Federal Court of Appeal released its first decision providing guidance on the standard for obtaining leave to appeal interlocutory decisions under section 6.11(1) of the Patented Medicines (Notice of...more
Update: The Federal Court updated the Guidelines on May 18, 2021, which can be found here.
The Federal Court has released a new consolidated practice direction, Case and Trial Management Guidelines for Complex...more
11/30/2020
/ Amended Regulation ,
Canada ,
Case Management ,
Complex Litigation ,
Discovery ,
Document Productions ,
Evidence ,
Expert Witness ,
Health Canada ,
Patented Medicines ,
Patents ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Trials